The Board of Dabur Pharma Ltd. (NSE: DABURPHARM, BSE: 532545) met today to consider the audited financial results of the company for the quarter & fiscal ended 31st March 2008.

FY 08 Highlights

· Consolidated Revenues at Rs. 2783 million in FY08 as against Rs. 3267 million in FY 07

· Consolidated PAT at Rs.986 million in FY 08 as against Rs.197 million in FY 07

The company’s overall sales during 07-08 were lower than last year on account of the divesture of non-oncology business to Alembic in March ’07. However, on a like to like basis, the oncology business recorded a sales growth of over 11% on a consolidated basis and 5% on a standalone basis.

The year also saw the Company’s Oncology Formulations business growth at a robust 30%. The Bulk Actives business, however, saw a decrease in overall sales compared to last year on account of increased captive consumption for the formulations business.

Commenting on the results, Mr. Ajay Kumar Vij, CEO, Dabur Pharma Limited, said “FY 2007-08 has been a good year for the company. It was the first full year of operations as a pure oncology player and the focus has started yielding positive results which is clearly visible in the excellent Oncology Formulations growth. This coupled with the major investments that we have been making in research and international market development will ensure that the growth momentum is aptly maintained well into the future.”

He further mentioned that the approval of indigenously developed “Nanoxel” (Nanoparticles Paclitaxel) for additional indications by the Drug Controller General of India (DCGI) is an excellent example of how the company’s commitment towards research is bearing fruit.

- End -

ABOUT DABUR PHARMA

Dabur Pharma Ltd. is committed to the discovery, development and marketing of drugs that fight cancer. Dedicated to its mission of making cancer therapy available to more and more people, it has been expanding ever since inception. The Company is the leader in the Indian Oncology market and it offers a complete range of products in this segment spanning across Injectables, Orals, Intermediates and APIs and is present in over 40 countries.